Correction to "Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis". [PDF]
europepmc +1 more source
Baseline Dual-Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate-Lowering Therapy. [PDF]
Tabi-Amponsah AD +10 more
europepmc +1 more source
Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. [PDF]
Sanchez C +6 more
europepmc +1 more source
Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. [PDF]
Tedeschi SK +4 more
europepmc +1 more source
Urate-lowering therapy is associated with a reduced risk of arrhythmias: a systematic review and meta-analysis. [PDF]
Waitayangkoon P +8 more
europepmc +1 more source
I142 Urate-lowering therapy: what is the optimum target serum urate level?
openaire +1 more source
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. [PDF]
Holladay EE +7 more
europepmc +1 more source
I156 What’s New? Emerging Approaches to Urate-Lowering Therapy [PDF]
openaire +1 more source
Erratum: Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study [Corrigendum]. [PDF]
europepmc +1 more source
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]
europepmc +1 more source

